Analysts think APLS stock price could increase by 88%
Nov 11, 2025, 12:25 PM
29.76%
What does APLS do
Apellis Pharmaceuticals, based in Waltham, Massachusetts, specializes in developing therapies for diseases with high unmet needs, employing 702 staff since its IPO in November 2017. Its approved products include SYFOVRE for geographic atrophy and pegcetacoplan for paroxysmal nocturnal hemoglobinuria.
21 analysts think APLS stock price will increase by 87.70%. The current median analyst target is $35.70 compared to a current stock price of $19.02. The lowest analysts target is $18.18 and the highest analyst target is $63.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.